Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine - Related Studies

Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine

This study has been completed.

Study NCT00000635. Last updated on June 23, 2005. Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Herpes Simplex
		HIV Infections

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Infection

3	More general conditions related to this trial
		DNA Virus Infections
		Herpesviridae Infections
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Skin Diseases
		Skin Diseases, Infectious
		Skin Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Trifluridine
		Bacitracin zinc/Polymyxin B sulfate

5	Additional drug interventions recognized in this trial
		Bacitracin
		Polymyxin B
		Polymyxins

6	More general drug interventions related to this trial
		Anti-Bacterial Agents
		Anti-Infective Agents
		Anti-Infective Agents, Local
		Antimetabolites
		Antiviral Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses

7	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)
		Glaxo Wellcome